|
Minahans to receive honor from organ donation group
Tbo.com PALMA CEIA — Two longtime supporters of organ donation and transplant will be honored with an award to be named for them. Bill and Martha Minahan, who reside in Hunter’s Green in New Tampa, will be the first recipients of the Bill & Martha Minahan … |
FDA Approves Teva's TREANDA® (bendamustine HCI) Injection, a New Liquid … – DailyFinance
|
FDA Approves Teva’s TREANDA® (bendamustine HCI) Injection, a New Liquid …
DailyFinance TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
Bullish On Halozyme With Short Term Catalysts And Large Buy By A Jazz … – Trefis
|
Bullish On Halozyme With Short Term Catalysts And Large Buy By A Jazz …
Trefis The second therapy is MabThera SC, or Rituximab, with trade name Rituxan. Rituxan was approved in the US in 1997 for the treatment of non-Hodgkin’s lymphoma. With validation of the approval of the monoclonal antibody Herceptin SC, it’s looking like … |
BIOLINERX LTD. : BioLineRx Announces Receipt of a Notice of Allowance from … – 4-traders (press release)
BIOLINERX LTD. : BioLineRx Announces Receipt of a Notice of Allowance from …4-traders (press release)According to a 2011 report from Decision Resources, about 180 million people worldwide are chronically infected with HCV. In addition, HCV infection …
TEVA PHARMACEUTICAL INDUSTRIES LIMITED : FDA Approves Teva's … – 4-traders (press release)
Monthly Prescribing Reference |
TEVA PHARMACEUTICAL INDUSTRIES LIMITED : FDA Approves Teva’s …
4-traders (press release) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … New Treanda Formulation ApprovedMonthly Prescribing Reference FDA approves Teva’s injectable TreandaGlobes |
FDA approves Teva's injectable Treanda – Globes
|
FDA approves Teva’s injectable Treanda
Globes … (FDA) has approved a new injectable version Treanda for treatment of indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and chronic lymphocytic leukemia. |
Why Belgian and Dutch organ donation data are so different – Livemint
LivemintWhy Belgian and Dutch organ donation data are so differentLivemintThe Netherlands got this number of 28% after a very heavy advertising campaign, with millions spent on publicity, public outreach and a soap opera to make people sensitive to don…
First Lady champions mobile blood donation units – Capital FM Kenya
Capital FM Kenya |
First Lady champions mobile blood donation units
Capital FM Kenya Gachoka will take part in the Bank of America Chicago Marathon 2013 to raise funds for purchase of mobile blood donation units in the country. Gachoka’s initiative was sparked by numerous appeals for blood in the media. She decided to participate in … |
Teva's (TEVA) TREANDA Approved by US FDA – StreetInsider.com (subscription)
|
Teva’s (TEVA) TREANDA Approved by US FDA
StreetInsider.com (subscription) TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |
FDA Approves Teva's TREANDA(R) (bendamustine HCI) Injection, a New Liquid … – MarketWatch
|
FDA Approves Teva’s TREANDA(R) (bendamustine HCI) Injection, a New Liquid …
MarketWatch TREANDA is indicated for use in patients with indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen, and in patients with chronic lymphocytic leukemia … |